Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Withdrawn 1Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Liposarcoma 1Leiomyosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 225Cyclophosphamide 194Radiotherapy 181Nivolumab 181Carboplatin 155Paclitaxel 114Cisplatin 113Dexamethasone 111Radiosurgery 103Magnetic Resonance Spectroscopy 98Surveys and Questionnaires 92Ipilimumab 82Doxorubicin 80Lenalidomide 77durvalumab 76Rituximab 75atezolizumab 73Radiation 72venetoclax 69Standard of Care 69fludarabine 68Gemcitabine 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Docetaxel 60Oxaliplatin 59Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × sotigalimab × Clear all
NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Yale University

Phase 1 Active not recruiting
26 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Columbia University

Phase 2 Active not recruiting
27 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡